External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Basit Öğe Kaydı
dc.authoridErturk, Ismail/0000-0001-6835-0988
dc.authoridUcar, Gokhan/0000-0002-7649-1075
dc.authoridAksoy, Sercan/0000-0003-4984-1049
dc.authoridYekedüz, Emre/0000-0001-6819-5930
dc.authorwosidErturk, Ismail/B-4317-2019
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.authorwosidUcar, Gokhan/AAA-8198-2021
dc.authorwosidArslan, Cagatay/I-1932-2016
dc.authorwosidAksoy, Sercan/S-2480-2019
dc.authorwosidYekedüz, Emre/ABA-5814-2020
dc.contributor.authorYekeduz, Emre
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorErturk, Ismail
dc.contributor.authorTural, Deniz
dc.contributor.authorUcar, Gokhan
dc.contributor.authorOztas, Nihan Senturk
dc.contributor.authorArikan, Rukiye
dc.date.accessioned2024-06-12T11:13:43Z
dc.date.available2024-06-12T11:13:43Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIn this report, we validated a novel prognostic model structured by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) for patients with metastatic renal cell carcinoma. The former favor-able risk group was divided into 2 new categories: very favorable and favorable. Patients with very favorable risk had better survival than those with the novel favorable risk. Further studies are needed to evaluate whether less intensive therapies could be as effective as current combinations of therapies in the very favorable risk group. Background: A novel prognostic model was recommended for patients with metastatic RCC (mRCC) by the Interna-tional mRCC Database Consortium (IMDC). In this study, we aimed to externally validate a novel risk model for the IMDC-favorable risk group in patients with mRCC. Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) is a multicenter registry that includes 13 cancer centers in Turkey. As described by Schmidt et al., 3 parameters (ie, time from diagnosis to systemic therapy < 3 vs. >3 years, Kar nofsky Perfor mance Status [KPS] 80 vs. > 80, and the presence of brain, liver, or bone metastasis) were used to divide the IMDC favorable risk group into 2 new categories: very favorable and favorable risk groups. The primary endpoint was overall survival (OS). Time to treatment failure (TTF) and objective response rate (ORR) in the very favorable and favorable risk groups were the secondary endpoints. Results: A total of 545 patients with mRCC from all IMDC risk groups and 112 patients from the favorable risk group were included in this study. According to the novel classification model, 44 (39.3%) and 68 (60.7%) patients with former favorable risk were categorized into very favorable and favorable risk groups, respectively. The median OS (55.8 months vs. 34.2 months, P = .025) and TTF (25.5 months vs. 15.5 months, P = .010) were longer in the very favorable risk group than in the favorable risk group. The concordance index of the new IMDC model in all patients was 0.65 for OS. Despite the higher ORR in the very favorable risk group than in the favorable risk group, the difference between the groups was not statistically significant (52.4% vs. 44.7, P = .573). Conclusions: This was the first study to externally validate the novel IMDC risk model presented in the American Society of Clinical Oncology Genitourinary Cancers Symposium 2021.en_US
dc.identifier.doi10.1016/j.clgc.2022.07.006
dc.identifier.endpage182en_US
dc.identifier.issn1558-7673
dc.identifier.issn1938-0682
dc.identifier.issue1en_US
dc.identifier.pmid35970759en_US
dc.identifier.scopus2-s2.0-85136765917en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage175en_US
dc.identifier.urihttps://doi.org/10.1016/j.clgc.2022.07.006
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23663
dc.identifier.volume21en_US
dc.identifier.wosWOS:000926838900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCig Media Group, Lpen_US
dc.relation.ispartofClinical Genitourinary Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRisk Groupsen_US
dc.subjectVery Favorableen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subject1st-Line Treatmenten_US
dc.subjectSunitiniben_US
dc.titleExternal Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Databaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu